| USP订购编号 |
美国药典，USP分析标准品，英文名称，规格 |
CAS编号查询 |
UN编号对照 |
| USP-1708751 |
Valrubicin Resolution Mixture (25 mg) (valrubicin spiked with seven related substances) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1708762 |
Valsartan (350 mg) |
137862-53-4 |
|
| 2933995300 |
|
|
|
| USP-1708773 |
Valsartan Related Compound A (10 mg) (N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}D-valine) |
137862-87-4 |
|
| 2933998350 |
|
|
|
| USP-1708784 |
Valsartan Related Compound B (10 mg) (N-butyryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]methyl}-L-valine) |
952652-79-8 |
|
| 2933997500 |
|
|
|
| USP-1708795 |
Valsartan Related Compound C (10 mg) (N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester) |
137863-20-8 |
|
| 2933997500 |
|
|
|
| USP-1708810 |
Valsartan Related Compound E (15 mg) (N-valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine methyl ester) |
137863-17-3 |
|
| 2933997500 |
|
|
|
| USP-1709007 |
Vancomycin Hydrochloride (500 mg) |
1404-93-9 |
|
| 2941906000 |
|
|
|
| USP-1709018 |
Vancomycin B with Monodechlorovancomycin (300 mg) |
1404-93-9 |
|
| 2941906000 |
|
|
|
| USP-1709029 |
Vancomycin B (350 mg) |
1404-93-9 |
UN3288 |
| USP-1710006 |
Vanillin (200 mg) |
121-33-5 |
|
| 2912410000 |
|
|
|
| USP-1711009 |
Vanillin Melting Point Standard (1 g) (Approximately 82 degrees) |
121-33-5 |
|
| 2912410000 |
|
|
|
| USP-1711010 |
Vardenafil Hydrochloride (200 mg) |
330808-88-3 |
UN2811 |
| USP-1711029 |
Vardenafil System Suitability (20 mg) |
N/A |
UN2811 |
| USP-1711031 |
Vasicine (20 mg) |
6159-56-4 |
|
| 2939800000 |
|
|
|
| USP-1711064 |
Vardenafil Related Compound D (25 mg) (2-{2-Ethoxy-5-[(4-ethyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-imidazo[5,1-f][1,2,4]triazin-4(3H)-one) |
448184-48-3 |
|
| 2935909550 |
|
|
|
| USP-1711075 |
Vardenafil Related Compound E (25 mg) (2-[2-Ethoxy-5-(piperazin-1-ylsulfonyl)phenyl]-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(3H)-one) |
448184-46-1 |
|
| 2935909550 |
|
|
|
| USP-1711100 |
Vasopressin (1.71 mg) (Vasopressin, 8-L-arginine) (需冷链运输) |
113-79-1 |
|
| 2937190000 |
|
|
|
| USP-1711133 |
Lypressin (2 mg) (8-L-lysine vasopressin) (需冷链运输) |
50-57-7 |
|
| 2937190000 |
|
|
|
| USP-1711155 |
Vecuronium Bromide (50 mg) |
50700-72-6 |
|
| 2933399095 |
|
|
|
| USP-1711166 |
Vecuronium Bromide Related Compound A (25 mg) (3alpha,17Beta-diacetyl-oxy-2Beta, 16Beta-bispiperidinyl-5alpha-androstan) |
13529-31-2 |
|
| 2933399095 |
|
|
|
| USP-1711177 |
Vecuronium Bromide Related Compound B (15 mg) (Piperidinium, 1-[(2beta, 3alpha, 5alpha, 16beta, 17beta)-3-acetyloxy-17-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide) |
50587-95-6 |
|
| 2933399095 |
|
|
|
| USP-1711188 |
Vecuronium Bromide Related Compound C (15 mg) (Piperidinium, 1-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-dihydroxy-2-(1-piperidinyl) androstan-16-yl]-1-methyl bromide) |
73319-30-9 |
|
| 2933399095 |
|
|
|
| USP-1711202 |
Verapamil Hydrochloride (200 mg) |
152-11-4 |
UN2811 |
| USP-1711224 |
Vecuronium Bromide Related Compound F (15 mg) (Piperidinium,1-[(2beta,3alpha,5alpha,16beta,17beta)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide) |
73319-13-8 |
|
| 2933399095 |
|
|
|
| USP-1711268 |
Venlafaxine Hydrochloride (100 mg) |
99300-78-4 |
UN3077 |
| USP-1711279 |
Venlafaxine Related Compound A (10 mg) (1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride) |
93413-90-2 |
|
| 2922504500 |
|
|
|
| USP-1711304 |
Verapamil Related Compound A (50 mg) (3,4-Dimethoxy-alpha-[3-(methylamino)propyl]-alpha-(1-methylethyl)-benzeneacetonitrile monohydrochloride) |
67775-97-7 |
|
| 2926900005 |
|
|
|
| USP-1711406 |
Verapamil Related Compound B (50 mg) (4-[(3,4-Dimethoxyphenethyl)(methyl)amino]-2-(3,4-dimethoxyphenyl)-2-isopropylbutanenitrile hydrochloride) |
1794-55-4 |
|
| 2926900005 |
|
|
|
| USP-1711439 |
Verapamil Related Compound E (50 mg) (3,4-dimethoxybenzaldehyde) |
120-14-9 |
|
| 2912499500 |
|
|
|
| USP-1711461 |
Verteporfin (200 mg) |
129497-78-5 |
|
| 2933997500 |
|
|
|
| USP-1711472 |
Verteporfin Related Compound A (50 mg) ((+/-)18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]prophine-9,13-dipropanoic acid) |
N/A |
|
| 2933997500 |
|
|
|
| USP-1712001 |
Vigabatrin (200 mg) |
68506-86-5 |
|
| 2922498050 |
|
|
|
| USP-1712023 |
Vigabatrin Related Compound B (30 mg) ((E)-2-(2-aminoethyl)but-2-enoic acid hydrochloride) |
N/A |
|
| 2922498050 |
|
|
|
| USP-1712045 |
Vigabatrin Related Compound E (30 mg) (2-(2-aminobut-3-enyl)malonic acid) |
N/A |
|
| 2922498050 |
|
|
|
| USP-1714528 |
Vinorelbine Related Compound A (25 mg) (4-O-Deacetylvinorelbine tartrate) |
N/A |
UN1544 |
| USP-1714608 |
Vinpocetine (100 mg) |
42971-09-5 |
|
| 2939800000 |
|
|
|
| USP-1714619 |
Vinpocetine Related Compound A (30 mg) (ethyl (12S,13aS,13bS)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]-naphthyridine-12-carboxylate) |
40163-56-2 |
|
| 2939790000 |
|
|
|
| USP-1714620 |
Vinpocetine Related Compound B (30 mg) (Methyl(13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]-naphthyridine-12-carboxylate) |
4880-92-6 |
|
| 2939800000 |
|
|
|
| USP-1714641 |
Vinpocetine Related Compound C (30 mg) (ethyl (13aS,13bS)-13a-ethyl-10-methoxy-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate) |
N/A |
|
| 2933998350 |
|
|
|
| USP-1714652 |
Vinpocetine Related Compound D (30 mg) (ethyl(12R,13aS,13bS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate) |
57327-92-1 |
|
| 2939800000 |
|
|
|
| USP-1450404 |
Naftifine Hydrochloride (200 mg) |
65473-14-5 |
UN3077 |
| USP-1453005 |
Naloxone (200 mg) |
465-65-6 |
|
| 2939190000 |
|
|
|
| USP-1453504 |
Naltrexone (200 mg) |
16590-41-3 |
|
| 2939190000 |
|
|
|
| USP-1457006 |
Naphazoline Hydrochloride (200 mg) |
550-99-2 |
UN2811 |
| USP-1457017 |
Naphazoline Related Compound A (30 mg) (N-(2-Aminoethyl)-2-(naphthalen-1-yl)acetamide) |
36321-43-4 |
|
| 2924296000 |
|
|
|
| USP-1457083 |
Naphthalene (200 mg) |
91-20-3 |
UN1334 |
| USP-1457301 |
Naproxen (200 mg) |
22204-53-1 |
UN2811 |
| USP-1457312 |
Naproxen Related Compound A (20 mg) (6-methoxy-2-naphthoic acid) |
2471-70-7 |
|
| 2918992090 |
|
|
|
| USP-1457403 |
Naproxen Sodium (200 mg) |
26159-34-2 |
|
| 2918992090 |
|
|
|
| USP-1457414 |
Naproxen Related Compound K (50 mg) (1-(6-Methoxynaphthalen-2-yl)ethanol) |
77301-42-9 |
|
| 2918992090 |
|
|
|
| USP-1457425 |
Naproxen Related Compound L (15 mg) (1-(6-methoxynaphthalen-2-yl)ethanone) |
3900-45-6 |
|
| 2918992090 |
|
|
|
| USP-1457436 |
Naproxen Related Compound G (50 mg) ((R)-2-(6-Methoxynaphthalen-2-yl)propanoic acid) |
23979-41-1 |
UN2811 |
| USP-1457469 |
Naratriptan Hydrochloride (125 mg) |
143388-64-1 |
|
| 2935904000 |
|
|
|
| USP-1457491 |
Naratriptan Resolution Mixture (20 mg) |
N/A |
|
| 3822190000 |
|
|
|
| USP-1457505 |
Natamycin (200 mg) |
7681-93-8 |
|
| 2941906000 |
|
|
|
| USP-1457550 |
Naringin (200 mg) |
10236-47-2 |
|
| 2938900000 |
|
|
|
| USP-1457607 |
Nateglinide (200 mg) |
105816-04-4 |
|
| 2924296000 |
|
|
|
| USP-1457618 |
Nateglinide Related Compound A (10 mg) (trans-4-isopropylcyclohexanecarboxylic acid) |
7077/5/6 |
|
| 2916205000 |
|
|
|
| USP-1457629 |
Nateglinide Related Compound B (10 mg) (N-(trans-4-isopropylcyclohexanecarbonyl)-L-phenylalanine) |
105816-05-5 |
|
| 2924296000 |
|
|
|
| USP-1457630 |
Nateglinide Related Compound C (20 mg) (N-(cis-4-isopropylcyclohexanecarbonyl)-D-phenylalanine) |
105816-06-6 |
|
| 2924296000 |
|
|
|
| USP-1457695 |
Negundoside (50 mg) ((1S,4aS,7S,7aS)-1,4a,5,6,7,7a-Hexahydro-7-hydroxy-1-{[2-O-(4-hydroxybenzoyl)-beta-D- glucopyranosyl] |
82451-20-5 |
|
| 2938900000 |
|
|
|
| USP-1457709 |
Vitex negundo Leaf Dry Extract (3 g) |
NA |
|
| 1302190200 |
|
|
|
| USP-1670218 |
Tolcapone Related Compound A (25 mg) (4′-methyl-3,4-dihydroxybenzophenone) |
N/A |
|
| 2914500000 |
|
|
|
| USP-1670229 |
Tolcapone Related Compound B (25 mg) (4-hydroxy-3-methoxy-4′-methyl-5-nitrobenzophenone) |
N/A |
|
| 2914710000 |
|
|
|
| USP-1671006 |
Tolnaftate (200 mg) |
2398-96-1 |
|
| 2930206050 |
|
|
|
| USP-1671468 |
Tolterodine S-Enantiomer (15 mg) ((S)-2-[3-(Diisopropylamino)-1-phenylpropyl]-4-methylphenol tartrate) |
873551-03-2 |
|
| 2922299000 |
|
|
|
| USP-1671480 |
Tolterodine Tartrate (200 mg) |
124937-52-6 |
|
| 2922299000 |
|
|
|
| USP-1672010 |
o-Toluenesulfonamide (200 mg) |
88-19-7 |
|
| 2935909550 |
|
|
|
| USP-1672020 |
p-Toluenesulfonamide (200 mg) |
70-55-3 |
|
| 2935909550 |
|
|
|
| USP-1672053 |
p-Toluidine (50 mg) (需冷链运输) |
106-49-0 |
UN3451 |
| USP-1672100 |
Tomato Extract Containing Lycopene (1 g) |
N/A |
|
| 1302190200 |
|
|
|
| USP-1672206 |
Topiramate (150 mg) |
97240-79-4 |
|
| 2935904000 |
|
|
|
| USP-1672210 |
Topiramate Related Compound A (25 mg) (2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose) |
20880-92-6 |
|
| 2932999000 |
|
|
|
| USP-1672257 |
Topotecan Hydrochloride (350 mg) |
1067286-75-2 |
UN1544 |
| USP-1672268 |
Topotecan Related Compound A (25 mg) ((S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-8-methoxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) |
N/A |
|
| 2939800000 |
|
|
|
| USP-1672280 |
Topotecan Related Compound C (25 mg) ((S)-4-Ethyl-4-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) |
7689/3/4 |
UN1544 |
| USP-1672304 |
Torsemide (200 mg) |
56211-40-6 |
|
| 2935904000 |
|
|
|
| USP-1672315 |
Torsemide Related Compound A (75 mg) (4-[(3-methylphenyl)amino]-3-pyridinesulfonamide) |
72811-73-5 |
|
| 2935909550 |
|
|
|
| USP-1672326 |
Torsemide Related Compound B (50 mg) (N-[(n-butylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide) |
160972-33-8 |
|
| 2935909550 |
|
|
|
| USP-1672337 |
Torsemide Related Compound C (30 mg) (N-[(ethylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide) |
58155-35-4 |
|
| 2935909550 |
|
|
|
| USP-1672359 |
Torsemide Related Compound E (20 mg) (4-(3-Tolyl)-2H-pyrido[4,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide) |
72810-61-8 |
|
| 2934990005 |
|
|
|
| USP-1672621 |
Tramadol Related Compound B (25 mg) (2-(dimethylaminomethyl)-1-cyclohexanone hydrochloride) |
42036-65-7 |
|
| 2922390000 |
|
|
|
| USP-1672687 |
Trandolapril (125 mg) |
87679-37-6 |
|
| 2933995300 |
|
|
|
| USP-1672698 |
Trandolapril Related Compound A (25 mg) ((2S,3aR,7aS)-1-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]hexahydro-2-indolinecarboxylic acid 1-methyl ester) |
N/A |
|
| 2933998350 |
|
|
|
| USP-1672701 |
Trandolapril Related Compound C (25 mg) ((2S, 3aR, 7aS)-1-[N-[(S)-1-Carboxy-3-cyclohexylpropyl]-L-alanyl]hexahydro-2-indolinecarboxylic acid 1-ethyl ester hydrochloride) |
N/A |
|
| 2933999552 |
|
|
|
| USP-1672712 |
Trandolapril Related Compound D (25 mg) ((S)-ethyl 2-[(3S, 5aS, 9aR, 10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl]-4-phenylbutanoate) |
149881-40-3 |
|
| 2933997500 |
|
|
|
| USP-1672723 |
Trandolapril Related Compound E (25 mg) ((2S,3aR,7aS)-1-[N-[(S)-1-Carboxy-3-phenylpropyl]-L-alanyl]hexahydro-2-indolinecarboxylic acid) |
87679-71-8 |
|
| 2933999552 |
|
|
|
| USP-1672745 |
Tranexamic Acid (200 mg) |
1197-18-8 |
|
| 2922498050 |
|
|
|
| USP-1672756 |
Tranexamic Acid Related Compound C (15 mg) ((RS)-4-(Aminomethyl)cyclohex-1-enecarboxylic acid hydrochloride) |
N/A |
|
| 2922498050 |
|
|
|
| USP-1672803 |
Transplatin (25 mg) |
14913-33-8 |
UN2811 |
| USP-1672905 |
Tranylcypromine Sulfate (125 mg) |
13492-01-8 |
UN2811 |
| USP-1672916 |
Tranylcypromine Related Compound A (40 mg) ((+/-)-cis-2-phenylcyclopropanamine hydrochloride; cis-tranylcypromine hydrochloride) |
54779-58-7 |
|
| 2921490002 |
|
|
|
| USP-1672927 |
Tranylcypromine Related Compound B (40 mg) ((E)-3-Phenylallylamine hydrochloride) |
17480-08-9 |
|
| 2921490002 |
|
|
|
| USP-1673500 |
Trazodone Hydrochloride (200 mg) |
25332-39-2 |
|
| 2933595960 |
|
|
|
| USP-1673533 |
Trazodone Related Compound C (20 mg) (2-{3-[4-(4-chlorophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one hydrochloride) |
1263278-77-8 |
|
| 2933599550 |
|
|
|
